Bladder cancer is a huge economic burden on the healthcare system and is responsible for approximately 5% of all cancer deaths in humans. Mycobacterium bovis BCG-based therapy is the treatment of choice for superficial bladder cancer. Bacillus Calmette-Guerin (BCG) instillation in the bladder results in a massive local inflammatory response that has secondary antitumor properties. Recent studies have demonstrated that neutrophils present in the bladder after BCG instillation release large amounts of the apoptosis-inducing molecule TRAIL, as well as chemokines that recruit other immune cells, suggesting that neutrophils play a key role in the antitumor response to BCG therapy. This review discusses the impact of these findings on the understanding of the antitumor mechanisms underlying BCG-based immunotherapy for bladder cancer.
|Original language||English (US)|
|Number of pages||15|
|State||Published - Nov 2007|
Bibliographical noteFunding Information:
Acknowledgments This work was supported by the University of Iowa Infectious Diseases Postdoctoral Training Grant (MPS), grant AI034879–19 from the National Institutes of Health (WMN), Carver Medical Research Initiative Grant administered through the University of Iowa Carver College of Medicine (TSG), and grant CA109446 from the National Cancer Institute (TSG).